| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,630,000,000 |
| Market
Cap: |
384.35(B) |
| Last
Volume: |
6,182,604 |
Avg
Vol: |
8,314,942 |
| 52
Week Range: |
$144.45 - $174.48 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
DOW JONES COMPOSITE |
| |
DOW JONES INDUSTRIAL AVERAGE |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
| |
MAJOR MARKET |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 21 |
| Guru Rank Value : 20.3 |
| Guru Occurances : 6 |
|
|
|
|
|
| |
|
Company Profile Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of products in the health care field. Co. has three business segments: Consumer Health, which includes products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension; and Medical Devices, which includes products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
68,288 |
68,288 |
115,451 |
522,170 |
| Total Sell Value |
$10,723,734 |
$10,723,734 |
$18,652,688 |
$88,845,171 |
| Total People Sold |
2 |
2 |
5 |
10 |
| Total Sell Transactions |
2 |
2 |
5 |
24 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wolk Joseph J |
Exec VP, CFO |
• • – |
2023-08-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(67) |
50,275 |
|
- |
|
| Duato Joaquin |
CEO and Chairman of the Board |
• • – |
2023-08-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,035) |
305,358 |
|
- |
|
| Hait William |
See Remarks |
• • – |
2023-08-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(696) |
87,051 |
|
- |
|
| Fasolo Peter |
Exec VP, Chief HR Officer |
• • – |
2023-08-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(232) |
102,464 |
|
- |
|
| Mcevoy Ashley |
EVP, WW Chair, MedTech |
• • – |
2023-08-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,787) |
52,038 |
|
- |
|
| Hait William |
See Remarks |
• • – |
2023-07-26 |
4 |
S |
$172.00 |
$2,528,056 |
D/D |
(14,698) |
87,747 |
|
8% |
|
| Hait William |
See Remarks |
• • – |
2023-07-26 |
4 |
OE |
$90.44 |
$1,329,287 |
D/D |
14,698 |
102,445 |
|
- |
|
| Fasolo Peter |
Exec VP, Chief HR Officer |
• • – |
2023-07-25 |
4 |
S |
$170.32 |
$3,406,498 |
D/D |
(20,000) |
102,696 |
|
10% |
|
| Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
• • – |
2023-06-12 |
4 |
S |
$160.00 |
$1,994,400 |
D/D |
(12,465) |
65,934 |
|
5% |
|
| Wolk Joseph J |
Exec VP, CFO |
• • – |
2023-05-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
55 |
50,342 |
|
- |
|
| Reed John C |
EVP, Pharmaceuticals R&DOffice |
• – – |
2023-04-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
306 |
|
11% |
|
| Swanson James D. |
See Remarks |
• • – |
2023-03-06 |
4 |
S |
$154.66 |
$164,199 |
D/D |
(1,062) |
9,215 |
|
-3% |
|
| Johnson Paula A |
Director |
– • – |
2023-02-14 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
102 |
|
- |
|
| Johnson Paula A |
Director |
– • – |
2023-02-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100 |
|
1% |
|
| Wolk Joseph J |
Exec VP, CFO |
• • – |
2023-02-13 |
4 |
D |
$162.01 |
$1,389,722 |
D/D |
(8,578) |
50,397 |
|
- |
|
| Wolk Joseph J |
Exec VP, CFO |
• • – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,693 |
58,975 |
|
- |
|
| Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
• • – |
2023-02-13 |
4 |
D |
$162.01 |
$792,391 |
D/D |
(4,891) |
78,399 |
|
- |
|
| Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
• • – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,839 |
83,290 |
|
- |
|
| Hait William |
See Remarks |
• • – |
2023-02-13 |
4 |
D |
$162.01 |
$742,978 |
D/D |
(4,586) |
87,747 |
|
- |
|
| Hait William |
See Remarks |
• • – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
9,640 |
92,333 |
|
- |
|
| Mongon Thibaut |
Exec VP, WW Chair, Cons Health |
• • – |
2023-02-13 |
4 |
D |
$162.01 |
$1,041,724 |
D/D |
(6,430) |
65,915 |
|
- |
|
| Mongon Thibaut |
Exec VP, WW Chair, Cons Health |
• • – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
13,710 |
72,345 |
|
- |
|
| Decker Robert J |
VP Corporate Controller |
• • – |
2023-02-13 |
4 |
D |
$162.01 |
$64,318 |
D/D |
(397) |
16,917 |
|
- |
|
| Decker Robert J |
VP Corporate Controller |
• • – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,451 |
17,314 |
|
- |
|
| Forminard Elizabeth |
Executive VP, General Counsel |
• • – |
2023-02-13 |
4 |
D |
$162.01 |
$149,697 |
D/D |
(924) |
5,484 |
|
- |
|
606 Records found
|
|
Page 4 of 25 |
|
|
0.68 (0.46%) 
